Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02999321 · ClinicalTrials.gov registry record · NA
The Effects of Aspartame on Appetite, Body Composition and Oral Glucose Tolerance
A NA study, sponsored by Purdue University.
- Completed
- Registry status
- NA
- Development phase
- 93
- Enrollment target
NCT02999321: Completed NA study, sponsored by Purdue University.
NCT02999321 is a NA study that has completed, run by Purdue University. The registered enrollment target is 93 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02999321, a NA study, has completed, sponsored by Purdue University.
- COMPLETED
- Registry status
- NA
- Development phase
- 93 participants
- Enrollment target
Study Summary
Assess the impact of chronic use of aspartame on glycemia, appetite and body composition.
Primary Outcome
sample taken at time point 0
Interventions
- OTHER water
- OTHER aspartame
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2016-08-17 |
| Est. Completion | 2017-05-05 |
| Phase | NA |
What the finished NCT02999321 record still lists
NCT02999321 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which water is the first listed.
NCT02999321 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02999321 about?
NCT02999321 is a clinical study titled "The Effects of Aspartame on Appetite, Body Composition and Oral Glucose Tolerance". Assess the impact of chronic use of aspartame on glycemia, appetite and body composition.
What is the current status of trial NCT02999321?
This trial is currently completed. It is a NA study. The enrollment target is 93 participants. The study started on 2016-08-17. Estimated completion is 2017-05-05.
What interventions are being tested in trial NCT02999321?
The interventions under investigation include: water (OTHER), aspartame (OTHER).
Who is sponsoring clinical trial NCT02999321?
This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02999321's enrollment target sits among peer trials
93 937th of 2000 higher than 1,064 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI